

ARMEPHACO JOINT STOCK COMPANY
AUDITED SEPARATE FINANCIAL STATEMENTS
For the year ended 31/12/2024

ARMEPHACO JOINT STOCK COMPANY

No. 118, Vu Xuan Thieu Street, Phuc Loi Ward, Long Bien District, Hanoi City, Vietnam

TABLE OF CONTENTS

<u>CONTENTS</u>	Page(s)
STATEMENT OF THE BOARD OF GENERAL DIRECTORS	1 - 2
INDEPENDENT AUDITORS' REPORT	3 - 4
AUDITED SEPARATE FINANCIAL STATEMENTS	
Separate Balance Sheet	5 - 6
Separate Income Statement	7
Separate Cash Flows Statement	8
Notes to the Separate financial statements	9 - 36



ARMEPHACO JOINT STOCK COMPANY

No. 118, Vu Xuan Thieu Street, Phuc Loi Ward, Long Bien District, Hanoi City, Vietnam

STATEMENT OF THE BOARD OF GENERAL DIRECTORS

The Board of General Directors of Armephaco Joint Stock Company presents this statements and the accompanying separate financial statements of the Company for the year ended 31st December 2024.

THE COMPANY

Armephaco Joint Stock Company (hereinafter referred to as the “the Company”) formerly known as Military Pharmaceutical and Medical Equipment Company was established under Decision No. 1436/QĐ-CP dated 12/8/1996 of the Ministry of Defence and operated under the Business Registration Certificate No. 110974 dated 21/8/1996 issued by Hanoi Department of Planning and Investment. The company was converted into a joint stock company under Decision No. 1183/QĐ-BQP dated 15/04/2010 of the Ministry of Defence and operated under the Business Registration Certificate of Joint Stock Company No. 0100109191 issued by Hanoi Department of Planning and Investment on 23/6/2010, Changes made several times and the 19th change on April 11, 2024 regarding the change of legal representative.

The charter capital according to the 19th amended Business Registration Certificate dated April 11, 2024 of the Company is 130,000,000,000 VND (In words: One hundred and thirty billion VND).

Company's Name: ARMEPHACO JOINT STOCK COMPANY.

The Company's Name in English: ARMEPHACO JOINT STOCK COMPANY.

The Company's stock is currently listed on the UpCOM with the code AMP.

The Company's registered office is located at: No. 118, Vu Xuan Thieu Street, Phuc Loi Ward, Long Bien District, Hanoi City, Vietnam.

BOARDS OF MANAGEMENT, SUPERVISORS AND GENERAL DIRECTORS

Members of Boards of Management, Supervisors and General Directors who held the Company during the year and at the date of this report are as follows:

Board of Management

Mr. Pham Cong Doan	Chairman (Appointed from 18/6/2024)
Mr. Doan Manh Cuong	Chairman (Dismissed from 18/6/2024)
Mr. Nguyen Van Dung	Vice Chairman (Dismissed from 18/6/2024)
Mrs. Nguyen Thi Huong	Member (Appointed from 18/6/2024)
Mrs. Nguyen Dieu Trinh	Member (Dismissed from 18/6/2024)
Mr. Nguyen Anh Dung	Member (Dismissed from 18/6/2024)
Ms. Vu Thi Cam Trang	Member (Appointed from 18/6/2024)

Board of Supervisors

Ms. Nguyen Thi Huong	Head of the Board (Appointed from 18/6/2024)
Mr. Nguyen Anh Tuan	Member (Dismissed from Head of the Board on 18/6/2024, Member from 18/6/2024)
Mr. Le Manh Hien	Member
Mrs. Nguyen Thi Huong Lien	Member (Dismissed from 18/6/2024)

Board of General Directors

Mr. Duong Dinh Son	General Director (Appointed from 10/4/2024; Dismissed from Deputy General Director on 10/4/2024)
Mr. Nguyen Van Dung	General Director (Dismissed from 10/4/2024)
Mr. Nguyen Anh Dung	Deputy General Director - In charge of finance (Dismissed from 01/07/2024)

ARMEPHACO JOINT STOCK COMPANY

No. 118, Vu Xuan Thieu Street, Phuc Loi Ward, Long Bien District, Hanoi City, Vietnam

STATEMENT OF THE BOARD OF GENERAL DIRECTORS(CONTINUED)

Board of General Directors (Continued)

Mrs. Nguyen Thi Huong Deputy General Director

Mr. Nguyen Thien Duc Deputy General Director - In Charge of Business (Appointed from 01/6/2024,
Dismissed from 01/11/2024)

Mr. Tong Van Bien Deputy General Director - In Charge of Business (Appointed from 03/3/2025)

SUBSEQUENT EVENTS

According to the Board of General Directors, in all material respects, there have been no other significant events occurring after the balance sheet date, affecting the financial position and operation of the Company which would require adjustments to or disclosures to be made in the separate financial statements for the year ended 31st December 2024.

AUDITORS

The Company's separate financial statements for the year ended 31st December 2024 have been audited by CPA VIETNAM Auditing Company limited - A Member Firm of INPACT.

THE BOARD OF GENERAL DIRECTORS' RESPONSIBILITY

The Company's Board of General Directors is responsible for preparing the separate financial statements, which give a true and fair view of the financial position as well as of its income and cash flows statements for the year then ended, complying with Vietnamese Standards on Accounting, Vietnamese Accounting System and relevant regulations in preparation and disclosure of separate financial statements. In preparing these financial statements, the Board of General Directors is required to:

- Select appropriate accounting policies and apply them consistently;
- Make judgments and estimates prudently;
- State clearly whether the Accounting Standards applied to the Company are followed or not, and all the material differences from these standards are disclosed and explained in the separate Financial Statements;
- Design and implement effectively the internal control system in order to ensure that the preparation and presentation of the separate Financial Statements are free from material misstatements due to frauds or errors;
- Prepare the separate Financial Statements of the Company on the going-concern basis, except for the cases that the going-concern assumption is considered inappropriate.

The Board of General Directors is responsible for ensuring that proper accounting records are kept, which disclose, with reasonable accuracy at any time, the financial position of the Company and to ensure that the separate financial statements comply with Vietnamese Standards on Accounting, Vietnamese Accounting System and relevant legal regulations in preparation and presentation of the separate financial statements. The Board of General Directors is also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of frauds and other irregularities.

The Board of General Directors confirms that the Company has complied with the above requirements in preparing the separate financial statements.

For and on behalf of the Board of General Directors,



Dương Dinh Son
General Director

Hanoi, 29th March 2025

Head Office in Hanoi:

8th floor, VG Building, No. 235 Nguyen Trai Str.,
Thanh Xuan Dist., Hanoi, Vietnam

+84 (24) 3 783 2121

info@cpavietnam.vn

+84 (24) 3 783 2122

www.cpavietnam.vn

No: 264/2025/BCKT-CPA VIETNAM-NV2

INDEPENDENT AUDITORS' REPORT

To: **Shareholders**
Boards of Management, Supervisors and General Directors
Armephaco Joint Stock Company

We have audited the accompanying separate financial statements of Armephaco Joint Stock Company, as set out on pages 05 to pages 35, prepared on 29/03/2025 including the separate Balance sheet as at 31/12/2024, and the separate Income Statement, and separate Cash flows Statement for the year then ended, and Notes to the separate financial statements

Responsibility of the Board of General Directors

The Company's Board General of Directors is responsible for the true and fair preparation and presentation of these separate financial statements in compliance with Vietnamese Accounting Standards, Vietnamese Accounting System and the statutory requirements relevant to the preparation and presentation of the separate financial statements, and for the internal control as the Board of General Directors determines is necessary to enable the preparation of Separate financial statements that are free from material misstatement, whether due to fraud or error.

Responsibility of Auditors

Our responsibility is to express an opinion on these separate financial statements based on our audit. We conducted our audit in accordance with Vietnamese Standards on Auditing. These Standards require us to comply with the Standards and codes of ethics, to plan and perform the audit to obtain reasonable assurance as to whether the Company's separate financial statements are there any significant errors or not.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the separate financial statements. The audit procedures are selected based on the auditor's judgment, including the assessment of risks of material misstatement in the separate financial statements due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the separate financial statements in order to design appropriate audit procedures to the actual situation, which is not intended to give an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by management, as well as evaluating the overall presentation of the separate financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Auditors' Opinion

In our opinion, the accompanying separate financial statements gives a true and fair view of, in all material respects, the financial position of the Company as at 31st December 2024 and the results of its operations and its cash flows for the year then ended in accordance with Vietnamese Accounting Standards, Vietnamese Enterprise Accounting System and the statutory requirements relevant to preparation and presentation of the separate financial statements in Vietnam.



Nguyen Thi Mai Hoa**Deputy General Director**

Audit Practising Registration Certificate:

2326-2023-137-1

Authorised: 08/2025/UQ-CPA VIETNAM dated 02/01/2025 of Chairman

For and on behalf of

CPA VIETNAM AUDITING COMPANY LIMITED**A member firm of INPACT***Hà Nội, 29th March 2025*

Nguyen Thi Tien**Auditor**

Audit Practising Registration Certificate:

5276-2021-137-1

SEPARATE BALANCE SHEET
As at 31st December 2024

ASSET	Code	Note	31/12/2024	01/01/2024
			VND	VND
A - CURRENT ASSET	100		863,627,074,672	702,613,904,476
(100=110+120+130+140+150)				
I. Cash and cash equivalents	110	5.1	31,570,147,453	41,606,478,268
1. Cash	111		31,570,147,453	40,806,478,268
2. Cash equivalents	112		-	800,000,000
III. Other short term receivables	130		667,373,944,757	536,025,010,789
1. Receivables from customer	131	5.2	489,358,443,717	421,860,698,152
2. Advances to supplier	132	5.3	147,483,068,739	77,118,871,064
6. Other short term receivables	136	5.4	31,715,169,715	38,273,178,987
7. Provision for bad short-term receivables	137	5.5	(1,182,737,414)	(1,227,737,414)
IV. Inventories	140	5.6	161,511,282,085	124,393,736,467
1. Inventories	141		161,511,282,085	124,393,736,467
V. Other current assets	150		3,171,700,377	588,678,952
1. Short term prepaid expenses	151	5.10	48,239,563	83,178,543
2. Tax and amount receivables from State budget	152		3,111,001,169	505,500,409
3. Tax and amount receivables from State budget	153	5.13	12,459,645	-
B - NON-CURRENT ASSETS	200		142,754,312,724	137,312,839,278
(200=220+240+250+260)				
I. Long-term receivables	210		1,829,397,040	1,829,397,040
6. Other long-term receivables	216	5.4	1,829,397,040	1,829,397,040
II. Fixed assets	220		7,716,244,277	9,068,486,868
1. Tangible fixed assets	221	5.7	7,716,244,277	9,068,486,868
- Cost	222		35,238,071,068	35,238,071,068
- Accumulated depreciation	223		(27,521,826,791)	(26,169,584,200)
3. Intangible fixed assets	227	5.8	-	-
- Cost	228		1,020,285,000	1,020,285,000
- Accumulated amortization	229		(1,020,285,000)	(1,020,285,000)
IV. Long-term Construction in progress	240		1,228,574,518	-
2. Construction in progress	242		1,228,574,518	-
V. Long-term financial investments	250	5.9	131,165,940,000	126,265,940,000
1. Investment in the subsidiary	251		108,500,000,000	108,500,000,000
2. Investment in the associated and joint-venture companies	252		17,765,940,000	17,765,940,000
3. Investment in intities	253		22,000,000	22,000,000
4. Provision for long term investment devaluation	254		(22,000,000)	(22,000,000)
5. Held to maturity investments	255		4,900,000,000	-
VI. Other non-current asset	260		814,156,889	149,015,370
1. Long term prepaid expenses	261	5.10	814,156,889	149,015,370
TOTAL ASSETS (270 = 100+200)	270		1,006,381,387,396	839,926,743,754

SEPARATE BALANCE SHEET (CONTINUED)

As at 31st December 2024

RESOURCES	Code	Note	31/12/2024 VND	01/01/2024 VND
C- LIABILITIES (300=310+330)	300		826,094,008,568	681,887,113,214
I. Short term liabilities	310		825,159,556,568	680,952,661,214
1. Trade account payables	311	5.12	213,254,911,097	196,660,270,429
2. Advances from customers	312	5.13	108,191,597,668	39,949,871,571
3. Taxes and other payables to State budget	313	5.14	818,122,723	579,865,573
4. Payables to employees	314		1,753,363,535	1,687,952,205
5. Short-term accrued expenses	315	5.15	73,130,103,000	63,916,716,175
9. Other short-term payables	319	5.16	80,898,724,268	78,971,456,689
10. Short-term loans and liabilities	320	5.17	347,008,074,671	298,518,278,779
12. Bonus and welfare funds	322		104,659,606	668,249,793
II. Long-term liabilities	330		934,452,000	934,452,000
7. Other long-term payables	337	5.15	934,452,000	934,452,000
D- OWNERS' EQUITY (400 = 410+430)	400		180,287,378,828	158,039,630,540
I- Owners' equity	410	5.17	180,240,584,591	157,992,836,303
1. Paid in capital	411		130,000,000,000	130,000,000,000
- Common share with voting right	411a		130,000,000,000	130,000,000,000
7. Investment and development funds	418		18,691,061,355	18,691,061,355
10. Retained earnings	421		31,249,523,236	9,001,774,948
- LNST chưa phân phối lũy kế đến cuối kỳ trước	421a		28,707,976,948	6,962,232,203
- Retained earnings of this period	421b		2,541,546,288	2,039,542,745
11. Capital expenditure funds	422		300,000,000	300,000,000
II- Other resources and funds	430		46,794,237	46,794,237
2. Funds used for fixed asset acquisition	433		46,794,237	46,794,237
TOTAL RESOURCES (440 = 300+400)	440		1,006,381,387,396	839,926,743,754

Preparer



Nguyen Thi Huyen

Chief Accountant



Bui Xuan Binh

Ha Noi, 29th March 2025

General Director



Duong Dinh Son

SEPARATE INCOME STATEMENT

For the year ended 31st December 2024

ITEMS	Code	Note	In 2024	In 2023
			VND	VND
1. Gross sales of goods and services	01	6.1	619,866,492,406	532,263,054,675
2. Revenue deductions	02	6.1	-	51,837,975
3. Net sales of goods and services (10 = 01-02)	10	6.1	619,866,492,406	532,211,216,700
4. Cost of goods sold	11	6.2	593,199,947,521	505,517,010,297
5. Gross profit from sales of goods and services (20 = 10-11)	20		26,666,544,885	26,694,206,403
6. Financial income	21	6.3	13,878,729,257	14,696,846,468
7. Financial expenses	22	6.4	6,771,300,350	15,245,715,132
<i>In which: Interest expenses</i>	23		4,444,835,221	13,897,335,678
8. Selling expenses	25	6.5	14,672,117,727	10,632,632,321
9. General and administrative expenses	26	6.5	15,648,656,430	13,473,659,959
10. Operating profit {30 = 20+(21-22)-(25+26)}	30		3,453,199,635	2,039,045,459
11. Other income	31	6.6	9,085,663	101,979,424
12. Other expenses	32	6.6	920,739,010	101,491,138
13. Profit from other activities (40 = 31-32)	40	6.6	(911,653,347)	488,286
14. Accounting profit before tax (50 = 30+40)	50		2,541,546,288	2,039,533,745
15. Current income tax expense	51	6.7	-	-
16. Deferred tax income/(expense)	52		-	-
17. Profit after tax(60 = 50-51-52)	60		2,541,546,288	2,039,533,745

Preparer



Nguyen Thi Huyen

Chief Accountant



Bui Xuan Binh

Hanoi, 29th March 2025
General Director



Duong Dinh Son

SEPARATE CASH FLOW STATEMENT

(Indirect method)

For the year ended 31st December 2024

ITEMS	Code	Note	In 2024 VND	In 2023 VND
I. Cash flows from operating activities				
1. Profit before tax	01		2,541,546,288	2,039,533,745
2. Adjustments for				
- Depreciation and amortization	02		1,352,242,591	1,398,249,334
- Provisions	03		(45,000,000)	62,884,010
- Gain, loss from investment activities	05		(13,819,792,683)	(14,338,788,837)
- Interest expenses	06		4,444,835,221	13,897,335,678
3. Operating profit before movements in working capital	08		(5,526,168,583)	3,059,213,930
- (Increase) decrease receivables	09		(138,523,484,098)	49,782,719,825
- (Increase) decrease inventories	10		(37,117,545,618)	1,074,548,715
- (Increase) decrease accounts payable	11		125,642,047,136	(28,873,855,800)
- (Increase) decrease prepaid expenses	12		(630,202,539)	(123,948,213)
- Interest paid	14		(7,806,192,708)	(2,877,231,202)
- Other cash outflows	17		(563,590,187)	-
Net cash from operating activities	20		(64,525,136,597)	22,041,447,255
II. Payments for acquisition, construction of fixed assets and other long- term assets				
1. Purchase and constrution of fixed assets and other long-term assets	21		(1,228,574,518)	-
3. Payment for lending, purchasing debt instruments of other entities	23		(4,900,000,000)	-
7. Interest income, dividends received	27		12,127,584,408	31,636,448,049
Net cashflow from investing activities	30		5,999,009,890	31,636,448,049
III. Cash flows from financing activities				
3. Proceeds from borrowings	33		456,891,335,037	229,067,384,415
4. Payment to settle debts	34		(408,401,539,145)	(281,202,739,844)
Net cashflow from financing activities	40		48,489,795,892	(52,135,355,429)
Net cashflow during the period (50 = 20+30+40)	50		(10,036,330,815)	1,542,539,875
Cash and cash equivalents at beginning of year	60		41,606,478,268	40,063,938,393
Cash and cash equivalents at end of year (70 = 50+60+61)	70	5.1	31,570,147,453	41,606,478,268

Preparer

Chief Accountant

Ha Noi, 29th March 2025
General Director



Nguyen Thi Huyen



Bui Xuan Binh



Duong Dinh Son

NOTES TO THE SEPARATE FINANCIAL STATEMENTS

For the year ended 31st December 2024

1. COMPANY INFORMATION

1.1 Structure of ownership

Armephaco Joint Stock Company formerly known as Military Pharmaceutical and Medical Equipment Company was established under Decision No. 1436/QD-CP dated 12/8/1996 of the Ministry of Defence and operated under the Business Registration Certificate No. 110974 dated 21/8/1996 issued by Hanoi Department of Planning and Investment. The company was converted into a joint stock company under Decision No. 1183/QD-BQP dated 15/04/2010 of the Ministry of Defence and operated under the Business Registration Certificate of Joint Stock Company No. 0100109191 issued by Hanoi Department of Planning and Investment on 23/6/2010, Changes made several times and the 19th change on April 11, 2024 regarding the change of legal representative.

The charter capital according to the 19th amended Business Registration Certificate dated April 11, 2024 of the Company is 130,000,000,000 VND (In words: One hundred and thirty billion VND).

Company's Name: ARMEPHACO JOINT STOCK COMPANY.

The Company's Name in English: ARMEPHACO JOINT STOCK COMPANY.

The Company's stock is currently listed on the UpCOM with the code AMP.

The Company's registered office is located at: No. 118, Vu Xuan Thieu Street, Phuc Loi Ward, Long Bien District, Hanoi City, Vietnam

The total number of the Company's employees as at 31/12/2024: 56 employees (As at 31/12/2023: 65 employees).

1.2 Operating industries and principal activities

Lines of business according to the business registration of the Company:

- Wholesale of machinery, equipment and other machine spare parts – details: Wholesale of medical machinery and equipment; Wholesale of electrical machinery, equipment, electrical materials (generators, electric motors, wires and other equipment used in electrical circuits); Wholesale of machinery, equipment and other machine parts that have not been classified anywhere;
- Producing other chemical products that have not been classified anywhere (except those prohibited by the State);
- Installation of electrical systems; Installation of heating, drainage, heating and air conditioning systems;
- Other specialized wholesalers that have not been categorized; Detail:
- Wholesale of other chemicals (except those used in agriculture); Other specialized wholesalers have not been classified anywhere (except for those prohibited by the State); Trading in chemicals (except chemicals prohibited by the State);
- Water extraction, treatment and supply; Repair of electrical equipment; Installation of industrial machinery and equipment;
- Building houses of all kinds; Sewerage and wastewater treatment;
- Wholesale of solid, liquid, gaseous fuels and related products;
- Installation of other construction systems; Other specialized construction activities;
- Wholesale of other household utensils. Details: Wholesale of other household utensils; Drug wholesalers;
- Trading in real estate, land use rights belonging to owners, users or renters. Details: Real estate business;
- Vocational education; Warehousing and storage of goods; Freight transport by road;
- The remaining business support services have not been categorized. Details: Import and export of trading company items;
- Other Health Activities that have not been categorized. Details: Enterprises providing drug storage services; Enterprises providing drug testing services;
- Retail sale of medicines, medical instruments, cosmetics and hygiene items in specialized stores. Details: Retail sale of medical supplies, cosmetics and hygiene items in specialized stores; (For conditional business lines, enterprises only do business when they meet the conditions prescribed by law).

Main activities of the Company during the year: Manufacturing and selling drugs, medical devices and commercial services.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

1.3. Normal operating cycle

The Company's normal operating cycle is 12 months

1.4. Statement of information comparability on the separate financial statements

The Board of Directors ensures to follow all the requirements of the Vietnamese Accounting Standards and System, which were issued together with the Circular No. 200/2014/TT-BTC dated 22 December 2014 and Circular No. 53/2016/TT-BTC on amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC dated December 22, 2014 issued by the Ministry of Finance. Therefore, the information and figures presented in the separate financial statements are comparable..

1.5. The Company structure

As at 31/12/2024, the Company has subsidiaries and associates as follows:

Name	Address	Major business lines	Capital contribution ratio	Voting Ratio	Benefit ratio
Subsidiaries					
120 Armephaco One Member Company Limited	Ha Noi	Production of medicines, medicinal chemicals and medicinal herbs	100%	100%	100%
130 Armephaco Medical Equipment One Member Company Limited	Ha Noi	Manufacture of medical, dental, orthopaedic and rehabilitation equipment and instruments	100%	100%	100%
150 Cophavina Pharmaceutical One Member Company	Ho Chi Minh City	Production of medicines, medicinal chemicals and medicinal herbs	100%	100%	100%
Associates					
Vinahancook Medical Supplies CO., JSC	Ha Noi	Production of 1-time use syringes and production of medical instruments	32.3%	32.2%	32.3%

Dependent units as at 31/12/2024:

Name	Address
Branch of Armephaco Joint Stock Company - 150 Pharmaceutical Enterprise	112 Tran Hung Dao, Pham Ngu Lao Street, District 1, Ho Chi Minh City
Branch in Ho Chi Minh City	112 Tran Hung Dao, Pham Ngu Lao Street, District 1, Ho Chi Minh City
Branch in Can Tho City	Hung Phu New Urban Area, Cai Rang District, Can Tho
Hanoi Branch	No. 8 Tang Bat Ti, Pham Dinh Ho Ward, Hai Ba Trung District, Hanoi (Decommissioned since 2018)
Representative Office in Da Nang City	49/211 Le Dinh Duong Street, Phuoc Ninh Ward, Hai Chau District, Da Nang City

2. FISCAL YEAR AND ACCOUNTING CURRENCY

Fiscal years

The Company's fiscal year begins on 1st January and ends on 31st December of solar year.

Accounting currency

The accompanying separate financial statements are expressed in Vietnam Dong (VND).

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

3. ACCOUNTING STANDARDS AND SYSTEM

Accounting System

The Company applied to Vietnamese Accounting System promulgated under Circular No. 200/2014/TT-BTC dated 22 December 2014 issued by the Ministry of Finance and Circular No. 53/2016/TT-BTC dated March 21, 2016 amending and supplementing a number of articles of Circular 200/2014/TT-BTC.

Statements for the compliance with Accounting Standards and System

The Board of Directors ensures to follow all the requirements of the Vietnamese Accounting Standards and System, which were issued together with the Circular No. 200/2014/TT-BTC dated 22 December 2014 and Circular No. 53/2016/TT-BTC on amending and supplementing a number of articles of Circular No. 200/2014/TT-BTC dated December 22, 2014 issued by the Ministry of Finance. Therefore, the information and figures presented in the financial statements are comparable. The Board of Directors of the Company ensures that it has fully complied with the Vietnamese Accounting Standards and the Vietnamese Enterprise Accounting System that have been issued and come into effect in relation to the preparation and presentation of the separate financial statements for the financial year ended December 31, 2024.

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of preparation of the Separate financial statements

The attached Separate financial statements for the year ended December 31, 2024 are expressed in Vietnam Dong (VND), under the historical cost convention and in accordance with Vietnamese Accounting Standards, Vietnamese Accounting System and legal regulations relevant to the preparation and presentation of Separate financial statements for the year ended December 31, 2024.

The Company's separate financial statements are prepared on the basis of Separate the financial statements of the affiliated units and the financial statements of the Company's Office. Transactions and balances between the Company's Office and the affiliated units and between the affiliated units with each other have been eliminated when presenting the Company's separate financial statements.

The separate financial statements do not include the financial statements of the subsidiaries. Users of the separate financial statements should read them together with the Company's Separate financial statements for the year ended December 31, 2024 in order to have complete information on the financial position as well as the results of operations and cash flows of the Company during the year.

Accounting for operations arising in foreign currency

Operations arising in foreign currency are converted according to the exchange rate applicable at the time the business arises, the exchange rate difference arising from these operations is recognized as income and financial expenses in the Separate Income Statement.

Re-evaluation of foreign currency-based monetary items at the time of preparation of the Separate Financial Statements

- (i) Cash funds of foreign currency origin classified as liabilities (Payable to sellers, borrowers,...): Reassessed according to the selling rate of Joint Stock Commercial Bank for Foreign Trade of Vietnam at 31/12/2024.

Exchange rate differences arising from the revaluation are incorporated into Financial Revenues or expenses at the time of preparation of the Separate Financial Statements.

Accounting estimates

The preparation of the Separate financial statements in conformity with Vietnamese Accounting Standards requires the Board of General Directors to make estimates and assumptions that affect the reported amounts of liabilities, assets and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the fiscal year. Actual results may differ from those estimates and assumptions.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Cash and cash equivalents

Cash comprises cash on hand, bank deposits.

Cash equivalents are short-term investments that have a recovery or maturity period of no more than 3 months from the date of purchase, are easily converted into a specified amount of money as well as do not have much risk in converting into cash at the time of reporting.

Financial investments

Investments in Subsidiaries, associates and other investments

Investments in subsidiaries over which the Company has control, investments in associates and joint ventures over which the Company has significant influence are presented using the cost method in the separate financial statements..

Profit distributions that Company received from the accumulated profits of the subsidiaries after the Company obtains control right are recognized in income statement. Other distributions are considered a recovery of investment and are deducted to the investment value.

Investments in Subsidiaries, Joint Ventures, Associates and other investments are presented in the balance sheet at original cost less provisions for impairment (if any)..

Other investments are recorded at cost, including purchase price plus directly attributable acquisition costs. After the initial recognition, these investments are measured at cost less allowance for diminution in value of investments.

Allowance for loss of investments

Provisions for devaluation of investments in subsidiaries, joint ventures, associates and equity instruments of other entities are made when there is solid evidence showing a decline in the value of these investments at the end of the accounting period..

Receivables

The receivables comprise the customer receivables and other receivables. Receivables are recognized at the carrying amounts less allowances for doubtful debts.

Allowance for doubtful debts is assessed and made for overdue receivables that are difficult to be collected, or the debtor is unable to pay due to dissolution, bankruptcy or similar difficulties.

Inventories

Inventories is determined on the basis of cost price, in case the original price of inventories is higher than the net realizable value, it must be calculated according to the net realizable value. Inventories cost includes direct material costs, direct labor costs, and overhead production costs, if any, to obtain inventory at its current location and state. The net realizable value is determined by the estimated sales price minus the costs to complete and the marketing, sales, and distribution costs incurred. Inventories is accounted for by the nominal method.

The Company's allowance for impairment of inventories is made when there is reliable evidence of impairment of the net realizable value compared to the history cost of inventories.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Tangible fixed assets and Depreciation

Tangible fixed assets are stated at history cost less accumulated depreciation. Historical costs of tangible fixed assets include all the expenses paid by the Company to bring the asset to its working condition for its intended use.

Tangible fixed assets are depreciated using straight line method over their estimated useful lives. Details are as follows:

	<u>Years</u>
Buildings, structures	10 - 25
Machinery and equipment	06 - 20
Motor vehicles	06 - 08
Office equipment	05 - 08

When a tangible fixed asset is sold or disposed, its historical cost and accumulated depreciation are written off, then any gain or loss arising from such disposal is included in the income or the expenses during the year..

Intangible fixed assets and Amortization

Intangible fixed assets are reflected at cost, are stated at history cost less accumulated amortization.

Accounting software is amortized over 8 years.

Prepaid expenses

Prepaid expenses comprise actual expenses arising but relevant to financial performance in several accounting periods and the transfer of these expenses into production and business expenses of the following accounting periods.

Prepaid expenses: are recorded at original cost and classified into short-term and long-term on the separate Balance Sheet based on the allocation period..

Long-term prepaid expenses related to tools and instruments are initially reflected at the cost and allocated in a straight-line method over a period of 02 to 03 years.

Payables

The account payables are monitored in details by payable terms, payable parties, original currency and other factors depending on the Company's management requirement.

The account payables include payables as trade payables, loans payable, intercompany payable and other payables which are determined almost certainly about the recorded value and term, which is not carried less than amount to be paid. They are classified as follows:

- Trade payables: reflect payables of commercial nature arising from the purchase of goods, services, or assets, payables for import through trustees of which the seller is an independent entity with the Company (including payables between the parent company and its subsidiaries, associates). This payable includes amounts payable upon import through the trustee (in a trust import transaction).
- Other payables reflect payables of non-commercial nature and irrelevant to purchase, sales of goods or provisions of services.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Loans and finance lease liabilities

Loans and finance lease liabilities include loans, financial leases, excluding loans in the form of bonds or preference shares with terms that the issuer is required to repurchase at a certain point in the future.

The Company monitors loan amounts and financial liabilities in details by each type and classifies them into short-term and long-term according to repayment term.

Expenses directly related to the loan are recognized to financial expenses, except for expenses incurred from a separate loan for investment, construction or production in progress, which are capitalized according to Accounting Standard "Borrowing costs".

Owners' equity

Capital is recorded according to the actual amounts invested by owners.

Undistributed profit is determined on the basis of business results after corporate income tax and the distribution of profits of the Company.

Profit after corporate income tax is distributed to shareholders after being approved by the General Meeting of Shareholders at the Company's Annual General Meeting and after having set aside reserve funds in accordance with the Company's Charter.

Dividends are declared and paid based on the estimated amount of profit achieved. Dividends are officially announced and paid in the next year from undistributed profits based on the approval of the General Meeting of Shareholders at the Company's Annual General Meeting.

Revenue and other income

The Company's revenue includes revenue from sales of goods, revenue from services.

Revenue from sale of goods

Revenue from sale of goods shall be recognized when it satisfies all the five (5) conditions below:

- The Company has transferred to the buyer the significant risks and reward of ownership of the goods;
- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the Company; and
- Costs related to transactions can be determined.

Revenue from services

Revenue from services is recognized when the outcome of that transaction can be reliably determined. Where a transaction involving the rendering of services is attributable to several periods, revenue is recognized in the year by reference to the percentage of completion of the transaction at the balance sheet date of that period. The outcome of a transaction can be measured reliably when all four (4) following conditions are satisfied:

- The amount of revenue can be measured reliably;
- It is probable that the economic benefits associated with the transaction will flow to the Company;
- Identify the completed work as at the balance sheet date; and
- Determine the costs incurred for the transaction as well as the cost to complete the transaction to provide that service.

Revenue from interest income, dividends and profits received and other income:

The revenue is recognized when the Company can obtain economic benefits from the above activities and when it is reliably measured.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue deductions

Revenue deductions includes:

- Returned goods: due to violation of commitments, economic contracts, low quality or incorrect types and specifications.

In case goods sold or services provided in the previous period but sales discounts, sales allowances, sales returns incur in the following period, the Company recognises as the following principles:

- If incurred before issuance of financial statements: reducing revenue in the financial statements of the reporting period.
- If incurred after issuance of financial statements: reducing revenue of the occurrence period.

Cost of goods sold

- Includes the cost price of products, goods and services provided during the year (including depreciation expenses; repair costs;...,) recognized in accordance with revenue for the year.

Financial expenses

- Borrowing expenses: Monthly recognition based on the loan, loan interest rate and actual number of loan days.
- Exchange rate loss expense: Recognized when there is a difference between the actual transaction rate and the bookkeeping rate and when there is a loss when re-evaluating foreign currency-based currency items.

Current corporate income tax expense and deferred corporate income tax expense

Corporate income tax expenses (or corporate income tax income): is total current and deferred income tax expenses (or total current and deferred tax) in determining profit or loss of a period.

- Current income tax expenses: are corporate income tax payable calculated on taxable profit during the year and current corporate income tax rate. Current income tax is calculated on taxable income and applicable tax rate during the tax period. Difference between taxable income and accounting profit is from adjustment of differences between accounting profit and taxable income in accordance with current tax policies.

The Company has an obligation to pay corporate income tax at the rate of 20% on taxable profits.

The determination of the Company's income tax is based on current tax regulations. However, these regulations change from time to time and the final determination of corporate income tax depends on the examination results of the competent tax authorities.

Related parties

A party is considered a related party of the Company in case that party is able to control the Company or to cause material effects on the financial decisions as well as the operations of the Company. A party is also considered a related party of the Corporation in case that party is under the same control or is subject to the same material effects.

When considering the relationship of related parties, the nature of relationship is focused more than its legal form.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Segment reporting

A business segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or related services (by business segment) or in providing products or services within a particular economic environment (geographical area) which is subject to risks and returns that are different from those of other segments. The Board of General Directors believes that the main activities of the Company are manufacturing and trading drugs, medical equipment and commercial services, not organized into separate divisions and operating only in the territory of Vietnam. Therefore, the Company does not prepare a Divisional Report.

5. SUPPLEMENTARY INFORMATION TO ITEMS DISCLOSED IN THE BALANCE SHEET

5.1 Cash and cash equivalents

	31/12/2024	01/01/2024
	VND	VND
Cash	58,556,796	630,005,785
Bank deposits	31,511,590,657	40,176,472,483
Cash equivalents	-	800,000,000
-Term deposits under 3 months	-	800,000,000
Total	31,570,147,453	41,606,478,268

5.2 Receivables from customers

	31/12/2024	01/01/2024
	VND	VND
Short-term	489,358,443,717	421,860,698,152
Children's Hospital 1	4,941,749,000	9,726,949,000
Xuan Hieu Technique Trading Company Limited	60,450,631,975	54,537,097,076
TFA Technology Joint Stock Company	32,167,037,123	32,765,881,580
36.66 Joint Stock Company	12,101,341,607	12,101,341,607
HANCORP Joint Stock Company	6,206,938,506	17,206,938,506
Others	373,490,745,506	295,522,490,383
Total	489,358,443,717	421,860,698,152
<i>In which: Receivables from related parties Details in Note 7.1</i>	<i>1,592,910,050</i>	<i>1,382,000,050</i>

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.3 Repayments to suppliers

	31/12/2024 VND	01/01/2024 VND
Short-term	147,483,068,739	77,118,871,064
TFA Technology Joint Stock Company	20,690,981,187	20,690,981,187
Eromed Joint Stock Company	33,215,165,000	-
Qv Medical Equipment Company Limited	17,095,519,566	-
G5 Hoang Gia Company Limited	14,847,080,961	8,347,362,791
Others	61,634,322,025	48,080,527,086
Total	147,483,068,739	77,118,871,064

5.4 Other receivables

Unit: VND

	31/12/2024		01/01/2024	
	Book value	Allowances	Book value	Allowances
Short-term	31,715,169,715	-	38,273,178,987	-
Other receivables	18,629,088,208	-	26,874,282,802	-
- Dividends income and profit	14,560,631,991	-	22,992,830,855	-
- Vinahankook Medical Supplies Co., Jsc	35,829,509,802	-	11,320,495,018	-
- 130 Armephaco Medical Equipment One Member Limited Company	1,496,250,815	-	1,066,927,959	-
- 120 Armephaco One Member Company Limited	3,632,621,505	-	3,715,511,133	-
- 150 Cophavina Pharmaceutical One Member Company Limited	3,135,299,671	-	4,014,931,618	-
- Others	4,068,456,217	-	3,881,451,947	-
- Advances	13,049,158,677	-	10,954,689,176	-
- Deposits	36,922,830	-	444,207,009	-
Short-term	1,829,397,040	-	1,829,397,040	-
- Deposits	1,829,397,040	-	1,829,397,040	-
Tổng	33,544,566,755	-	40,102,576,027	-

In which: Other receivables from related parties details in Note 7.1

14,560,631,991

22,992,830,855

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.5 Bad debts

Unit: VND

	31/12/2024		01/01/2024	
	Original value	Recoverable amount	Original value	Recoverable amount
Total value of receivables, loans that are overdue or not pass due but hardly recoverable;	1,182,737,414	-	1,227,737,414	-
<i>In Which:</i>				
	Overdue 6 month	Overdue 1 year to 2 years	Overdue 2 years to 3 years	Overdue for more than 3 years
Viet Hai Trading and Technical Services Company Limited	-	-	-	286,716,981
Hai Hoang Import Export and Equipment Company Limited	-	-	-	122,490,501
Nguyen Van Luan - Branch of Medical Equipment Technical Center	-	-	-	77,693,846
Mai Thanh Pharmaceutical Company Limited	-	-	-	117,007,180
Others	-	-	-	578,828,906
Total	-	-	-	1,182,737,414

5.6 Inventories

Unit: VND

	31/12/2024		01/01/2024	
	Original value	Allowances	Original value	Allowances
Raw materials	1,709,209,445	-	1,709,209,445	-
Tools and supplies	86,417	-	86,417	-
Work in progress	10,699,654,025	-	6,887,004,122	-
Goods	149,102,332,198	-	115,797,436,483	-
Total	161,511,282,085	-	124,393,736,467	-

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)
For the year ended 31st December 2024

5.7 Tangible fixed assets

Unit:: VND

HISTORY COST	Buildings and Structures	Machinery, equipment	Transportation means	Office equipment	Total
As at 01/01/2024	18,687,994,038	14,546,387,539	1,076,509,255	927,180,236	35,238,071,068
Increase	-	-	-	-	-
Decrease	-	-	-	-	-
As at 31/12/2024	18,687,994,038	14,546,387,539	1,076,509,255	927,180,236	35,238,071,068
ACCUMULATED DEPRECIATION					
As at 01/01/2024	10,959,022,518	13,231,161,285	1,076,509,255	902,891,142	26,169,584,200
Increase	775,919,347	560,406,346	-	15,916,898	1,352,242,591
Depreciation	775,919,347	560,406,346	-	15,916,898	1,352,242,591
Decrease	-	-	-	-	-
As at 31/12/2024	11,734,941,865	13,791,567,631	1,076,509,255	918,808,040	27,521,826,791
NET BOOK VALUE					
As at 01/01/2024	7,728,971,520	1,315,226,254	-	24,289,094	9,068,486,868
As at 31/12/2024	6,953,052,173	754,819,908	-	8,372,196	7,716,244,277

History cost of tangible fixed assets which are fully depreciated but still in use as at 31/12/2024 is :14,152,902,124 VND (As at 31/12/2023 is 14,025,217,124 VND).
Net book value of tangible fixed assets used to secure bank loans as at 31/12/2024: 3,435,164,451 VND (As at 31/12/2023 is 4,361,524,239 VND).

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)
For the year ended 31st December 2024

5.8 Intangible fixed assets

Unit: VND

	Software	Total
HISTORY COST		
As at 01/01/2024	1,020,285,000	1,020,285,000
Increase	-	-
Purchase	-	-
Decrease	-	-
As at 31/12/2024	1,020,285,000	1,020,285,000
ACCUMULATED AMORTIZATION		
As at 01/01/2024	1,020,285,000	1,020,285,000
Increase	-	-
Amortization	-	-
Decrease	-	-
As at 31/12/2024	1,020,285,000	1,020,285,000
NET BOOK VALUE		
As at 01/01/2024	-	-
As at 31/12/2024	-	-

The historical cost of intangible fixed assets which have been fully amortized but still in use as at 31/12/2024 is VND 1,020,285,000 (As at 31/12/2024 is VND 1,020,285,000).

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.9 Financial investments

a. Long-term investments

Unit: VND

	Ratio		31/12/2024			01/01/2024		
	Equity owned	Voting rights	Original cost	Provision	Fair value	Original cost	Provision	Fair value
Investment in the subsidiary								
120 Armephaco One Member Company Limited	100%	100%	108,500,000,000	-	-	108,500,000,000	-	-
130 Armephaco Medical Equipment One Member Limited Company	100%	100%	45,000,000,000	-	-	45,000,000,000	-	-
150 Cophavina Pharmaceutical One Member	100%	100%	18,500,000,000	-	-	18,500,000,000	-	-
Investments in joint ventures and associates			45,000,000,000	-	-	45,000,000,000	-	-
Vinahankook Medical Supplies			17,765,940,000	-	-	17,765,940,000	-	-
Joint Stock Company	32%	32%	17,765,940,000	-	-	17,765,940,000	-	-
Investments in other entities			22,000,000	(22,000,000)	-	22,000,000	(22,000,000)	-
Comtoir Pharmaceutique Du Viet Nam	10%	10%	22,000,000	(22,000,000)	-	22,000,000	(22,000,000)	-
Total			126,287,940,000	(22,000,000)	(*)	126,287,940,000	(22,000,000)	(*)

(*) The Company has not determined the fair value of these financial instruments for disclosure in the separate financial statements because there are no quoted prices on the market for these financial instruments and the current Vietnamese Accounting Standards and Vietnamese Enterprise Accounting Regime do not provide guidance on how to calculate fair value using valuation techniques. The fair value of these financial instruments may differ from their carrying value..

Transactions between the Company and its subsidiaries and associates during the year are presented in Note 7.1..

b. Investments held to maturity

	31/12/2024		01/01/2024	
	Original cost	Book value	Original cost	Book value
Long-term				
Term deposits at Joint Stock Commercial Bank for Investment and Development of Vietnam Thanh Do Branch (*)	4,900,000,000	4,900,000,000	-	-
	4,900,000,000	4,900,000,000	-	-
Total	154,002,332,198	154,002,332,198	-	-

(*): Term deposit at Joint Stock Commercial Bank with term of 13 months and interest rate from 4.2% to 4.7%/year.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.10 Prepaid expenses

	31/12/2024 VND	01/01/2024 VND
Short-term	48,239,563	83,178,543
Prepaid materials, tools and supplies expenses	48,239,563	83,178,543
Long-term	814,156,889	149,015,370
Prepaid materials, tools and supplies expenses	814,156,889	149,015,370
Total	862,396,452	232,193,913

5.11 Trade payables

Unit: VND

	31/12/2024		01/01/2024	
	Book value	Repayable amount	Book value	Repayable amount
Short-term	213,254,911,097	213,254,911,097	196,660,270,429	196,660,270,429
Trade payables	213,254,911,097	213,254,911,097	196,660,270,429	196,660,270,429
Apac Pharmaceuticals And Chemical Ltd	-	-	10,814,157,585	10,814,157,585
Medison- Viet Nam Company Limited	2,000,000,000	2,000,000,000	2,163,628,000	2,163,628,000
Smart Solutions Trading Corp	2,968,200,883	2,968,200,883	2,968,200,883	2,968,200,883
Gisp Vietnam Technologies Corporation	32,104,282	32,104,282	20,749,200,000	20,749,200,000
Bac Ha Technology and Investment Joint Stock Co	1,250,799,100	1,250,799,100	28,398,247,100	28,398,247,100
Meditop International Trading Joint Stock Company	391,740,000	391,740,000	391,740,000	391,740,000
Thai Son Medical Equipment Company Limited	4,410,778,703	4,410,778,703	8,185,978,703	8,185,978,703
T&T Pharmaceutical Joint Stock Company	14,375,218,305	14,375,218,305	14,375,218,305	14,375,218,305
Amec Holdings Company Limited	17,777,365,000	17,777,365,000	19,177,365,000	19,177,365,000
Others	170,048,704,824	170,048,704,824	89,436,534,853	89,436,534,853
Total	213,254,911,097	213,254,911,097	196,660,270,429	196,660,270,429

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.12 Short-term prepayments from customers

	31/12/2024 VND	01/01/2024 VND
Hanoi Construction Corporation - JSC	16,132,636,500	16,132,636,500
Institute of Geology	42,215,938,543	-
Project Management Board for Investment and Construction of Civil and Industrial Works of Quang Ninh Province	3,931,559,756	4,322,497,473
Imexpharm Corporation	-	6,411,490,313
G5 Hoang Gia Company Limited	-	-
Others	45,911,462,869	13,083,247,285
Total	108,191,597,668	39,949,871,571

5.13 Taxes and payables to, receivables from the State Treasury

Unit: VND

	01/01/2024	Additions	Paid	31/12/2024
Payables	579,865,573	11,554,930,776	11,316,673,626	818,122,723
VAT	1,379,120	10,591,486,423	10,592,865,543	-
Personal income tax	578,486,453	957,444,353	717,808,083	818,122,723
License tax	-	6,000,000	6,000,000	-
Receivables	-	-	12,459,645	12,459,645
VAT	-	-	12,459,645	12,459,645

5.14 Short-term accrued expenses

	31/12/2024 VND	01/01/2024 VND
Short-term	73,130,103,000	63,916,716,175
Interest expenses	73,130,103,000	63,916,716,175
Total	73,130,103,000	63,916,716,175

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.15 Other payables

	31/12/2024	01/01/2024
	VND	VND
Short-term	80,898,724,268	78,971,456,689
Trade Union fees	2,803,038,990	2,676,831,964
Social insurance	83,493,931	377,710,358
Others	77,992,191,347	75,045,064,617
<i>Dividend, Profit payables</i>	<i>877,584,667</i>	<i>26,877,584,667</i>
<i>Rent for Family Area X130</i>	<i>450,000,000</i>	<i>450,000,000</i>
<i>Viet My Medical Investment Joint Stock Company</i>	<i>13,482,401</i>	<i>13,482,401</i>
<i>The land lease payment to the Ministry of Defense (*)</i>	<i>46,695,588,644</i>	<i>38,102,997,523</i>
<i>Nguyen Van Dung</i>	<i>9,745,360,000</i>	<i>-</i>
<i>Thai Son Company</i>	<i>552,742,873</i>	<i>552,742,873</i>
<i>130 Armephaco Medical Equipment One Member Limited Company</i>	<i>10,480,394,847</i>	<i>1,931,324,872</i>
<i>150 Cophavina Pharmaceutical One Member Company Limited</i>	<i>5,397,805,169</i>	<i>-</i>
<i>Others</i>	<i>3,779,232,746</i>	<i>7,116,932,281</i>
Short-term deposits received	20,000,000	871,849,750
Long-term	934,452,000	934,452,000
Long-term deposits received	934,452,000	934,452,000
Total	81,833,176,268	79,905,908,689
 <i>In which: Details in Note 7.1</i>	 <i>15,878,200,016</i>	 <i>1,931,324,872</i>

(*) Land rent payable to the Ministry of National Defence according to Land Lease Contract No. 3258/HD-BQP dated October 2011 on the lease of 14,176 m2 of land in Ngoc Hoi Commune, Thanh Tri District, Hanoi; Land Lease Contract No. 3259/HD-BQP dated October 2011 on the lease of 15,276 m2 of land at 118B Vu Xuan Thieu, Phuc Loi Ward, Long Bien District, Hanoi City; Land Lease Contract No. 3260/HD-BQP dated October 2011 on the lease of 11,000 m2 of land at 118A Vu Xuan Thieu, Phuc Loi Ward, Long Bien District, Hanoi City; Contract 3261/HD-BQP on the lease of 1,266.5 m2 of land at No. 8 Tang Bat Ho, Pham Dinh Ho Ward, Hai Ba Trung District, Hanoi City.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)
For the year ended 31st December 2024

5.16 Borrowings and finance lease liabilities

Unit: VND

	31/12/2024		During the year		01/01/2024	
	Carrying value	Repayable amount	Increase	Decrease	Carrying value	Repayable amount
Short-term borrowings	347,008,074,671	347,008,074,671	456,891,335,037	408,401,539,145	298,518,278,779	298,518,278,779
SaiGon - HaNoi Commercial Joint Stock Bank (1)	69,439,855,972	69,439,855,972	146,728,223,180	158,973,380,905	81,685,013,697	81,685,013,697
Joint Stock Commercial Bank for Investment and Development of Vietnam -Thanh Đô Branch (2)	48,816,777,719	48,816,777,719	120,054,215,473	121,217,458,431	49,980,020,677	49,980,020,677
Tien Phong Commercial Joint Stock Bank - Thang Long Branch (3)	84,955,440,980	84,955,440,980	152,312,896,384	83,717,942,559	16,360,487,155	16,360,487,155
Joint Stock Commercial Bank For Foreign Trade Of Vietnam - Hanoi Branch (4)	-	-	-	30,492,757,250	30,492,757,250	30,492,757,250
Personal loan	143,796,000,000	143,796,000,000	37,796,000,000	14,000,000,000	120,000,000,000	120,000,000,000
Total	347,008,074,671	347,008,074,671	456,891,335,037	408,401,539,145	298,518,278,779	298,518,278,779

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)
For the year ended 31st December 2024

5.16 Borrowings and finance lease liabilities (Continued)

<1> Credit limit contract No. 0141/2024/HDHM-PN/SHB.110100 with Saigon - Hanoi Commercial Joint Stock Bank dated April 25, 2024 with a credit limit value of VND 300 billion. Purpose of use: Loan purpose, L/C issuance purpose, guarantee purpose, discount purpose; credit limit maintenance period is 12 months; loan interest rate is specified for each debt acknowledgment contract but maximum 9 months, late payment interest is maximum 50% of loan interest rate within term but not exceeding 10%/year. Security measures: No security measures; credit is only guaranteed for business plans signed with state agencies, hospitals, medical centers; projects with capital provided by the Ministry of Health, provincial budget capital, ODA capital managed by the Ministry of Finance.

<2> Credit limit contract No. 01/2024/1758456/HDTD with Vietnam Joint Stock Commercial Bank for Investment and Development dated December 5, 2024 with a credit limit of VND 80 billion. Of which, the loan limit; opening L/C and issuing payment guarantee is VND 60 billion; the guarantee limit (other than payment guarantee) is VND 20 billion. Purpose of use: Supplementing working capital, guarantee, issuing L/C. Limit granting period: from the date of signing the credit limit contract to November 30, 2025. The maximum loan term is 9 months for each loan withdrawal. Interest rate is determined according to the bank's interest rate regime for each period. Security measures are security contracts (Pledge/mortgage/guarantee/deposit contracts)

<3> Credit limit contract No. 104/2024/HDTD/TLG with Tien Phong Commercial Joint Stock Bank dated May 15, 2024 with a credit limit of VND 550 billion; of which the loan limit is VND 150 billion, the L/C limit is VND 300 billion, the guarantee limit is VND 300 billion. The above credit limit value includes the outstanding debt under the credit limit contract No. 116/2023/HDTD/TLG signed on June 20, 2023. Term of credit limit: 12 months from the date of signing the contract. Purpose of loan: supplementing working capital for production and business activities of pharmaceuticals and medical equipment. Flexible interest rates are specifically stipulated in each customer's debt acknowledgment document. The security measures are the following Mortgage Contracts: Mortgage Contract No. 85/2019/HDBD/TLG/01 dated March 13, 2019; Contract No. 133/2020/HDBD/TLG/13 dated November 3, 2021; Contract No. 228/2022/HDBD/TLG dated October 4, 2022; Contract No. 290/2022/HDBD/TLG dated October 21, 2022; Contract No. 308/2022/HDBD/TLG dated November 25, 2022; Contract No. 313/2022/HDBD/TLG dated December 5, 2022; Contract No. 317/2022/HDBD/TLG dated December 16, 2022; Contract No. 13/2023/HDBD/TLG dated January 13, 2023; Contract No. 12/2023/HDBD/TLG dated January 16, 2023.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.17 Owners' equity

a. Changes of owners' equity

Unit: VND

	Share capital	Development and Investment Fund	Retained profits	Fund for Construction	Total
As at 01/01/2023	130,000,000,000	18,583,441,412	33,177,481,089	300,000,000	182,060,922,501
Profit in the previous year	-	-	2,039,533,745	-	2,039,533,745
Deduction of development investment funds	-	107,619,943	(107,619,943)	-	-
Excerpt from the Reward Fund, welfare Dividends	-	-	(107,619,943)	-	(107,619,943)
As at 31/12/2023	130,000,000,000	18,691,061,355	(26,000,000,000)	-	(26,000,000,000)
As at 01/01/2024	130,000,000,000	18,691,061,355	9,001,774,948	300,000,000	157,992,836,303
Profit in this year	-	-	2,541,546,288	-	2,541,546,288
Adjustment of Vinahankook Dividends	-	-	(6,293,798,000)	-	(6,293,798,000)
Cancel Dividend 2017-2023 (i)	-	-	26,000,000,000	-	26,000,000,000
As at 31/12/2024	130,000,000,000	18,691,061,355	31,249,523,236	300,000,000	180,240,584,591

(i): The Company cancels the 2017-2023 dividend payment according to Resolution No. 279/NQ-ĐHĐCĐ dated June 18, 2024 Annual General Meeting of Shareholders 2024.

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

5.17 Owners' equity (Continued)

b. Details of owners' equity

	31/12/2024 VND	01/01/2024 VND
Department of Defense	37,700,000,000	37,700,000,000
Le Minh Thang	-	49,450,000,000
Nguyen Thi Huong	11,208,330,000	11,208,330,000
Nguyen Anh Dung	-	17,823,780,000
Viet Leader Asset Investment Company Limited	41,157,560,000	-
Pham Cong Doan	30,000,000,000	-
Capital contribution from other shareholders	9,934,110,000	13,817,890,000
Total	130,000,000,000	130,000,000,000

c. Capital transactions with shareholders and appropriation of profits and dividends

	In 2024 VND	In 2023 VND
Shareholders' capital		
Opening balance	130,000,000,000	130,000,000,000
Increased during the period	-	-
Decreased during the period	-	-
Closing balance	130,000,000,000	130,000,000,000
Dividend	(26,000,000,000)	26,000,000,000

d. Shares

	31/12/2024 Shares	01/01/2024 Shares
Quantity of registered shares	13,000,000	13,000,000
Quantity of issued shares	13,000,000	13,000,000
Common shares	13,000,000	13,000,000
Quantity of repurchased shares	-	-
Common shares	-	-
Quantity of outstanding shares	13,000,000	13,000,000
Common shares	13,000,000	13,000,000
Par value of outstanding shares (VND/ share)	10,000	10,000

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

6. ADDITIONAL INFORMATION ON THE ITEMS OF THE INCOME STATEMENT

6.1 Revenue from sales of goods and provision of services

	In 2024	In 2023
	VND	VND
Revenue from sales of goods	615,643,930,499	528,840,081,453
Revenue from provision of services	4,222,561,907	3,422,973,222
Total	619,866,492,406	532,263,054,675
Revenue deductions		
Sale return	-	51,837,975
Total	-	51,837,975
Net revenue		
Revenue from sales of goods	615,643,930,499	528,788,243,478
Revenue from provision of services	4,222,561,907	3,422,973,222
Total	619,866,492,406	532,211,216,700

6.2 Cost of goods sold

	In 2024	In 2023
	VND	VND
Cost of goods	593,199,947,521	505,446,855,438
Cost of provision of services	-	70,154,859
Total	593,199,947,521	505,517,010,297

6.3 Financial income

	In 2024	In 2023
	VND	VND
Interest income from deposits	136,590,255	103,568,641
Dividends received	13,683,202,428	14,235,220,196
Gains on realized exchange rate differences	58,936,574	358,057,631
Gains on unrealized exchange rate differences	-	-
Total	13,878,729,257	14,696,846,468
In which Financial income from related parties Details in Note	13,683,202,428	14,235,220,196

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

6.4 Financial expenses

	In 2024 VND	In 2023 VND
Interest expense	4,444,835,221	13,897,335,678
Losses on realized exchange rate differences	2,326,465,129	1,348,379,454
Total	6,771,300,350	15,245,715,132
In which Financial expenses from related parties Details in Note 7.1	200,547,945	-

6.5 Selling expenses and General and administrative expenses

	In 2024 VND	In 2023 VND
Selling expenses	14,672,117,727	10,632,632,321
Employee expenses	8,464,664,809	4,703,084,904
Materials expenses	19,475,889	50,374,322
Office supplies expenses	9,265,591	121,417,379
Warranty expense	27,868,889	49,316,000
Outsourcing expenses	5,395,233,406	4,347,621,588
Other cash expense	755,609,143	1,360,818,128
General and administrative expenses	15,648,656,430	13,473,659,959
Employee expenses	7,736,780,057	6,952,305,103
Materials expenses	570,069,057	297,155,206
Office supplies expenses	5,893,466	11,711,353
Amortization and Depreciation expenses	1,352,242,591	1,406,621,528
Charges and fee	1,831,851,865	1,731,180,099
Provision expenses	(45,000,000)	62,884,010
Outsourcing expenses	3,248,705,174	1,711,817,727
Other cash expense	948,114,220	1,299,984,933
Total	30,320,774,157	24,106,292,280

6.6 Other income/ Other expenses

	In 2024 VND	In 2023 VND
Other income		
Others	9,085,663	101,979,424
Total	9,085,663	101,979,424
Other expenses		
Late payment penalty, administrative violation	193,487,851	-
Others	727,251,159	101,491,138
Total	920,739,010	101,491,138
Other income	(911,653,347)	488,286

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

6.7 Current corporate income tax expense

	In 2024 VND	In 2023 VND
Total net profit before tax	2,541,546,288	2,039,533,745
Increase adjustment	-	-
Decrease adjustment	13,683,202,428	14,235,220,196
Dividends received	13,683,202,428	14,235,220,196
Taxable income	(11,141,656,140)	(12,195,686,451)
Corporate Income Tax rate	20%	20%
Current corporate income tax expense	-	-

6.8 Production and business expenses by factors

	In 2024 VND	In 2023 VND
Raw material expenses	614,454,003	490,408,260
Employee expenses	16,201,444,866	11,655,390,007
Amortization and Depreciation expenses	1,352,242,591	1,398,249,334
Provision expenses	(45,000,000)	62,884,010
Outsourcing expenses	12,430,362,955	6,059,439,315
Other cash expense	3,546,410,228	4,404,818,160
Total	34,099,914,643	24,071,189,086

7. OTHER INFORMATION

7.1 Information of related parties

List of Related parties:

<u>Related parties</u>	<u>Relations</u>
120 Armephaco Co., Ltd	Subsidiaries
130 Armephaco Medical Equipment Co., Ltd	Subsidiaries
Vinahankook medical supplies CO.,JSC	Associates
150 Cophavina Pharmaceutical one Member Company Limited	Subsidiaries
Members of the Board of Directors, the Executive Board, the Supervisory Board involved in managing the Corporation during the year and their close family members	Key Leadership Members

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

7.1 Information of related parties

In the year, the Company has transactions with related parties as follows:

Remuneration for Boards of Management, Supervisors and General Directors

Related parties	Nature of transaction	In 2024 VND	In 2023 VND
Remuneration for Board of Management and Supervisors	Salary and remuneration	964,549,998	545,500,000
Income of the Board of Directors, Chief accountant and other managers	Salary	2,302,324,000	1,959,235,209

In which:

Full name	Position	In 2024 VND	In 2023 VND
Nguyen Thanh Quang	Chairman (Dismissed from 26/06/2023)	-	68,000,000
Doan Manh Cuong	Chairman (Appointment from 18/06/2024)	56,000,000	48,000,000
Pham Cong Doan	Chairman (Appointment from 18/06/2024)	369,799,998	-
Nguyen Van Dung	Vice Chairman (Dismissed from 18/06/2024)	35,000,000	72,500,000
Nguyen Thi Huong	Member	115,310,000	72,500,000
Nguyen Anh Dung	Member (Dismissed from 18/06/2024)	35,000,000	72,500,000
Nguyen Dieu Trinh	Member (Dismissed from 18/06/2024)	35,000,000	72,500,000
Vu Thi Cam Trang	Member (Appointment from 18/06/2024)	82,560,000	-

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

7.1 Information of related parties (Continued)

Remuneration for Board of Supervisors

Full name	Position	In 2024 VND	In 2023 VND
Tran Tien Duc	Head of the Board (Dismissed from 30/11/ 2023)	-	47,500,000
Nguyen Anh Tuan	Member (Dismissed as Head of the Board on 18/06/2024, Member from 18/06/2024)	53,000,000	5,000,000
Nguyen Thi Huong	Head of the Board (Appointment from 18/6/2024)	122,880,000	-
Le Manh Hien	Member	39,000,000	43,500,000
Nguyen Thi Phuong Thao	Member (Dismissed from 26/06/ 2023)	-	25,500,000
Nguyen Thi Huong Lien	Member (Dismissed from 18/6/2024)	21,000,000	18,000,000

Remuneration for Boards of Management, Supervisors and General Directors

Remuneration for Board of General Directors and others

Full name	Position	In 2024 VND	In 2023 VND
Duong Dinh Son	General Director(Appointed General Director on 10/04/2024; Resigned Deputy General Director on 10/04/2024)	550,000,000	-
Nguyen Van Dung	General Director (Dismissed from 10/04/2024)	303,500,000	870,000,000
Nguyen Anh Dung	Deputy General Director (Dismissed from 01/07/2024)	282,500,000	580,000,000
Nguyen Thien Duc	Deputy General Director - Manager of Business Development	646,200,000	-
Bui Xuan Binh	Chief Accountant	428,900,000	408,100,000
Nguyen Thi Bich Hong	Secretary of the Board-Person Information Disclosure	-	40,000,000
Dang Hoai Anh	Secretary of the Board-Person Information Disclosure	-	41,962,609
Nguyen Thi Thanh Nhan	Secretary of the Board-Person Information Disclosure	91,224,000	19,172,600

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)For the year ended 31st December 2024**7.1 Information of related parties (Continued)****Related Party Balance**

Receivables	Relationships	31/12/2024 VND	01/01/2024 VND
<i>Receivables from customer</i>			
130 Arnephaco Medical Equipment Co., Ltd	Subsidiaries	1,382,000,050	1,228,901,323
<i>Other short term receivables</i>			
Vinahankook medical supplies CO.,JSC	Associates	-	920,000,050
120 Arnephaco Co., Ltd	Subsidiaries	-	43,807,867,581
130 Arnephaco Medical Equipment Co., Ltd	Subsidiaries	-	11,320,495,018
150 Cophavina Pharmaceutical one Member Company Limited	Subsidiaries	-	15,499,479,045
		-	3,937,765,734
		-	13,050,127,784
Debits		31/12/2024 VND	01/01/2024 VND
<i>Other payables</i>			
130 Arnephaco Medical Equipment Co., Ltd	Subsidiaries	15,878,200,016	1,931,324,872
150 Cophavina Pharmaceutical one Member Company Limited	Subsidiaries	10,480,394,847	1,931,324,872
		5,397,805,169	-

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)For the year ended 31st December 2024**7.1 Information of related parties (Continued)****Transactions with related parties**

Related parties	Relations	Nature of transaction	In 2024 VND	In 2023 VND
Purchase of goods				
120 Armephaco Co., Ltd	Subsidiaries	Goods	38,585,486,944	126,000,000
	Subsidiaries	lessor	41,666,667	126,000,000
			20,160,000	-
130 Armephaco Medical Equipment Co., Ltd	Subsidiaries	Goods	38,523,660,277	-
Dividends and profits				
Vinahankook medical supplies CO.,JSC	Associates	Profits	13,683,202,428	14,235,220,196
120 Armephaco Co., Ltd	Subsidiaries	Profits	6,296,460,000	8,955,227,000
			2,755,191,942	2,811,875,771
130 Armephaco Medical Equipment Co., Ltd	Subsidiaries	Profits	1,496,250,815	1,066,927,959
150 Cophavina Pharmaceutical one Member Company Limited	Subsidiaries	Profits	3,135,299,671	1,401,189,466
Others				
120 Armephaco Co., Ltd	Subsidiaries	Interest expense	200,547,945	-
			200,547,945	-

NOTES TO THE SEPARATE FINANCIAL STATEMENTS (CONTINUED)

For the year ended 31st December 2024

7.2 Comparative figures

Comparative figures on the balance sheet and related notes are taken from the separate financial statements for the year ended 31st December 2023 which are audited by CPA VIETNAM Auditing Company Limited – A Member of INPACT.

Preparer



Nguyen Thi Huyen

Chief Accountant



Bui Xuan Binh

Hanoi, 29th March 2025
General Director



Duong Dinh Son